These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 16037517)
1. Prognostic value of the standardized uptake value in esophageal cancer. van Westreenen HL; Plukker JT; Cobben DC; Verhoogt CJ; Groen H; Jager PL AJR Am J Roentgenol; 2005 Aug; 185(2):436-40. PubMed ID: 16037517 [TBL] [Abstract][Full Text] [Related]
2. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Kato H; Nakajima M; Sohda M; Tanaka N; Inose T; Miyazaki T; Fukuchi M; Oriuchi N; Endo K; Kuwano H Cancer; 2009 Jul; 115(14):3196-203. PubMed ID: 19472406 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Cheze-Le Rest C; Metges JP; Teyton P; Jestin-Le Tallec V; Lozac'h P; Volant A; Visvikis D Nucl Med Commun; 2008 Jul; 29(7):628-35. PubMed ID: 18528185 [TBL] [Abstract][Full Text] [Related]
4. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Pan L; Gu P; Huang G; Xue H; Wu S Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1008-15. PubMed ID: 19352191 [TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053 [TBL] [Abstract][Full Text] [Related]
7. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463 [TBL] [Abstract][Full Text] [Related]
8. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Omloo JM; Sloof GW; Boellaard R; Hoekstra OS; Jager PL; van Dullemen HM; Fockens P; Plukker JT; van Lanschot JJ Endoscopy; 2008 Jun; 40(6):464-71. PubMed ID: 18543134 [TBL] [Abstract][Full Text] [Related]
9. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography. Kato H; Fukuchi M; Miyazaki T; Nakajima M; Tanaka N; Inose T; Kimura H; Faried A; Saito K; Sohda M; Fukai Y; Masuda N; Manda R; Ojima H; Tsukada K; Oriuchi N; Endo K; Nonaka T; Shioya M; Ishikawa H; Sakurai H; Nakano T; Kuwano H Anticancer Res; 2007; 27(4C):2627-33. PubMed ID: 17695425 [TBL] [Abstract][Full Text] [Related]
10. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150 [TBL] [Abstract][Full Text] [Related]
11. [Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma]. Kong YH; Han CJ; Lee SD; Sohn WS; Kim MJ; Ki SS; Kim J; Jeong SH; Kim YC; Lee JO; Cheon GJ; Choi CW; Lim SM Korean J Hepatol; 2004 Dec; 10(4):279-87. PubMed ID: 15613803 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. Bütof R; Hofheinz F; Zöphel K; Stadelmann T; Schmollack J; Jentsch C; Löck S; Kotzerke J; Baumann M; van den Hoff J J Nucl Med; 2015 Aug; 56(8):1150-6. PubMed ID: 26089549 [TBL] [Abstract][Full Text] [Related]
13. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332 [TBL] [Abstract][Full Text] [Related]
18. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804 [TBL] [Abstract][Full Text] [Related]
19. The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma. Smith JW; Moreira J; Abood G; Aranha GV; Nagda S; Wagner RH; Shoup M Am J Surg; 2009 Mar; 197(3):308-12. PubMed ID: 19245906 [TBL] [Abstract][Full Text] [Related]
20. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. Downey RJ; Akhurst T; Ilson D; Ginsberg R; Bains MS; Gonen M; Koong H; Gollub M; Minsky BD; Zakowski M; Turnbull A; Larson SM; Rusch V J Clin Oncol; 2003 Feb; 21(3):428-32. PubMed ID: 12560430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]